Effective Cardiac Myocyte Differentiation of Human Induced Pluripotent Stem Cells Requires VEGF

Lei Ye, Sophia Zhang, Lucas Greder, James Dutton, Susan A. Keirstead, Mike Lepley, Liying Zhang, Dan Kaufman, Jianyi Zhang

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


Perhaps one of the most significant achievements in modern science is the discovery of human induced pluripotent stem cells (hiPSCs), which have paved the way for regeneration therapy using patients' own cells. Cardiomyocytes differentiated from hiPSCs (hiPSC-CMs) could be used for modelling patients with heart failure, for testing new drugs, and for cellular therapy in the future. However, the present cardiomyocyte differentiation protocols exhibit variable differentiation efficiency across different hiPSC lines, which inhibit the application of this technology significantly. Here, we demonstrate a novel myocyte differentiation protocol that can yield a significant, high percentage of cardiac myocyte differentiation (>85%) in 2 hiPSC lines, which makes the fabrication of a human cardiac muscle patch possible. The established hiPSCs cell lines being examined include the transgene integrated UCBiPS7 derived from cord blood cells and non-integrated PCBC16iPS from skin fibroblasts. The results indicate that hiPSC-CMs derived from established hiPSC lines respond to adrenergic or acetylcholine stimulation and beat regularly for greater than 60 days. This data also demonstrates that this novel differentiation protocol can efficiently generate hiPSC-CMs from iPSC lines that are derived not only from fibroblasts, but also from blood mononuclear cells.

Original languageEnglish (US)
Article numbere53764
JournalPloS one
Issue number1
StatePublished - Jan 17 2013


Dive into the research topics of 'Effective Cardiac Myocyte Differentiation of Human Induced Pluripotent Stem Cells Requires VEGF'. Together they form a unique fingerprint.

Cite this